These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22964698)

  • 41. Costs and clinical outcomes associated with use of ranolazine for treatment of angina.
    Phelps CE; Buysman EK; Gomez Rey G
    Clin Ther; 2012 Jun; 34(6):1395-1407.e4. PubMed ID: 22608105
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blockade of Na+ channels in pancreatic α-cells has antidiabetic effects.
    Dhalla AK; Yang M; Ning Y; Kahlig KM; Krause M; Rajamani S; Belardinelli L
    Diabetes; 2014 Oct; 63(10):3545-56. PubMed ID: 24812428
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of Angina: Where Are We?
    Balla C; Pavasini R; Ferrari R
    Cardiology; 2018; 140(1):52-67. PubMed ID: 29874661
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias.
    Stone PH
    Cardiol Clin; 2008 Nov; 26(4):603-14. PubMed ID: 18929234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ranolazine (Ranexa) in the treatment of chronic stable angina.
    Aslam S; Gray D
    Adv Ther; 2010 Apr; 27(4):193-201. PubMed ID: 20449698
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris.
    Bress AP; Dodson JA; King JB; Sauer BC; Reese T; Crook J; Radwanski P; Knippenberg K; Greene T; Nelson RE; Munger MA; Weintraub WS; LaFleur J
    Am J Cardiol; 2018 Dec; 122(11):1809-1816. PubMed ID: 30292334
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ranolazine: new approach for the treatment of stable angina pectoris.
    Stanley WC
    Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):821-9. PubMed ID: 16181027
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ranolazine: a review of its use in chronic stable angina pectoris.
    Siddiqui MA; Keam SJ
    Drugs; 2006; 66(5):693-710. PubMed ID: 16620147
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ranolazine: a potential new treatment for chronic stable angina.
    Anderson JR; Khou S; Nawarskas JJ
    Heart Dis; 2001; 3(4):263-9. PubMed ID: 11975803
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic angina.
    Muhlestein JB; Grehan S
    Drugs R D; 2013 Sep; 13(3):207-13. PubMed ID: 23990357
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of chronic stable angina pectoris.
    Rodríguez-Ospina L; Montano-Soto L
    Bol Asoc Med P R; 2008; 100(4):39-47. PubMed ID: 19400528
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis.
    Savarese G; Rosano G; D'Amore C; Musella F; Della Ratta GL; Pellegrino AM; Formisano T; Vitagliano A; Cirillo A; Cice G; Fimiani L; del Guercio L; Trimarco B; Perrone-Filardi P
    Int J Cardiol; 2013 Nov; 169(4):262-70. PubMed ID: 24063912
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders.
    Bhandari B; Subramanian L
    Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):35-9. PubMed ID: 18221101
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A focus on antiarrhythmic properties of ranolazine.
    Vizzardi E; D'Aloia A; Quinzani F; Bonadei I; Rovetta R; Bontempi L; Curnis A; Dei Cas L
    J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):353-6. PubMed ID: 22492919
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
    Melloni C; Newby LK
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antianginal Agents for the Management of Stable Ischemic Heart Disease: A Review.
    Mody P; Sidhu MS; Brilakis ES; Sacco JD; Banerjee S; Boden WE
    Cardiol Rev; 2016; 24(4):177-89. PubMed ID: 26274534
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Introduction: Managing patients with chronic angina: emerging therapeutic options for improving clinical efficacy and outcomes.
    Rumsfeld JS
    J Manag Care Pharm; 2006 Oct; 12(8 Suppl):S2-3. PubMed ID: 23577421
    [No Abstract]   [Full Text] [Related]  

  • 58. Update on the medical treatment of stable angina.
    Gayet JL; Paganelli F; Cohen-Solal A
    Arch Cardiovasc Dis; 2011 Oct; 104(10):536-44. PubMed ID: 22044707
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
    Koren MJ; Crager MR; Sweeney M
    J Am Coll Cardiol; 2007 Mar; 49(10):1027-34. PubMed ID: 17349881
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
    Sossalla S; Maier LS
    Pharmacol Ther; 2012 Mar; 133(3):311-23. PubMed ID: 22133843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.